Study reveals new insights into the molecular mechanisms of beta-amyloid buildup – a hallmark of Alzheimer’s disease – in the retina of people with AMD.
Nine strategies to reverse physician burnout
Building upon a decade of research on the rise and cost of physician burnout, researchers at the Mayo Clinic proposed nine strategies that health care organizations can implement to reverse the trend, limit the risk and promote physician well-being, according to a recent news release.“Research has shown that more than half of U.S. physicians are experiencing symptoms of burnout, and the rate is increasing,” Tait Shanafelt, MD, director of Mayo Clinic’s Program on Physician Well-being, said in the release. “Unfortunately, many organizations see burnout as a personal problem to be (Read more...)
Smart cane could transform lives of the blind and visually impaired
An enterprising researcher from The University of Manchester has developed a prototype tool that could help transform the lives of the blind and visually impaired.
PUBLICATION EXCLUSIVE: How to adjust IOL power in unusual cataract cases
With newly developed methods of IOL power calculation, we are approaching 90% or higher accuracy of being within 0.5 D of the intended refractive target. The Barrett Universal formula uses improved algorithms, the Hill-RBF method relies on artificial intelligence with large data sets, and the Ladas Super Formula incorporates both novel methods as well as crowd-sourced big data to continuously hone its results. But even with these techniques of calculation, there is still a need to adjust the IOL power in unusual cataract cases.The A-constant of the IOL reflects many (Read more...)
PUBLICATION EXCLUSIVE: Several options available to fix refractive misses in cataract surgery
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.As cataract surgery becomes more of a refractiv…
Allergan gets FDA approval for new XEN Glaucoma Treatment System
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.